CCM
BIO icon

Cloverdale Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Cloverdale Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-59,788
Closed -$11.9M – 11
2017
Q1 		$11.9M Sell
59,788
-9,770
-14% -$1.88M 7.2% 6
2016
Q4 		$12.7M Buy
+69,558
New +$11.9M 10.16% 3

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Cloverdale Capital Management's BIO Position: Q2 2017 in Review

Cloverdale Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2017, closing a stake of 59,788 shares — an estimated $11.9M sold.

Cloverdale Capital Management first reported a position in BIO in Q4 2016 and held it in 2 quarters. The position peaked at $12.7M in Q4 2016. 276 funds tracked by Wall St. Rank hold BIO as of Q2 2017.

  • Cloverdale Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q2 2017 after selling out during the quarter.
  • Cloverdale Capital Management sold 59,788 Bio-Rad Laboratories Class A shares in Q2 2017, an estimated $11.9M.
  • Cloverdale Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2016 and held it in 2 quarters.
  • Cloverdale Capital Management's Bio-Rad Laboratories Class A position peaked at $12.7M in Q4 2016.
  • 276 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2017.

Based on Cloverdale Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.